CryoPortCYRX
CYRX
About: CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
Employees: 1,186
0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 36
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
28% more call options, than puts
Call options by funds: $3.84M | Put options by funds: $2.99M
23% more capital invested
Capital invested by funds: $279M [Q1] → $343M (+$64.6M) [Q2]
3% more funds holding
Funds holding: 152 [Q1] → 157 (+5) [Q2]
0.04% less ownership
Funds ownership: 91.86% [Q1] → 91.81% (-0.04%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
15%
upside
Avg. target
$13.50
55%
upside
High target
$16
84%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Leerink Partners Puneet Souda | 84%upside $16 | Outperform Upgraded | 6 Aug 2025 |
Keybanc Paul Knight | 72%upside $15 | Overweight Upgraded | 6 Aug 2025 |
Stephens & Co. Helfey Hannah | 49%upside $13 | Overweight Assumed | 22 Jul 2025 |
BTIG David Larsen | 15%upside $10 | Buy Maintained | 7 Jul 2025 |
Financial journalist opinion
Based on 5 articles about CYRX published over the past 30 days
Positive
The Motley Fool
2 weeks ago
Cryoport (CYRX) Q2 Revenue Jumps 14%
Cryoport (CYRX) Q2 Revenue Jumps 14%
Neutral
Seeking Alpha
2 weeks ago
Cryoport, Inc. (CYRX) Q2 2025 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Jerrell W. Shelton - Chairman, President & CEO Mark W.
Negative
Zacks Investment Research
2 weeks ago
CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.33 per share a year ago.
Neutral
PRNewsWire
2 weeks ago
Cryoport Reports Second Quarter 2025 Financial Results
Second quarter revenue increased 14% year-over-year to $45.5 million Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million Life Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestiture Company reaffirms full year 2025 revenue guidance of $165 to $172 million NASHVILLE, Tenn. , Aug. 5, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2025.
Positive
Zacks Investment Research
4 weeks ago
CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Should You Buy?
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
1 month ago
CryoPort, Inc. (CYRX) Just Flashed Golden Cross Signal: Do You Buy?
CryoPort, Inc. (CYRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CYRX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Neutral
PRNewsWire
1 month ago
Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025
NASHVILLE, Tenn. , July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after U.S. markets close.
Neutral
PRNewsWire
1 month ago
Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers
New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology NASHVILLE, Tenn. , July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures.
Positive
Zacks Investment Research
1 month ago
What Makes CryoPort, Inc. (CYRX) a Strong Momentum Stock: Buy Now?
Does CryoPort, Inc. (CYRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
The Motley Fool
1 month ago
CEO Jerrell Shelton Sells Some Shares of Cryoport (CYRX)
According to the SEC Form 4 filing on June 26, 2025, Jerrell Shelton, president and CEO, exercised $5 per share options on 16,344 shares of Cryoport (CYRX 0.68%) and proceeded to sell them at $7.0586 per share (on average) on June 24, 2025, for a total sale price of $115,365.
Charts implemented using Lightweight Charts™